← Leaderboards
William H Gmeiner
University Of Nebraska Medical Center
$6,919,412
Attributed
$7,108,431
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,108,431 · 9
By mechanism
R42$1,983,010 · 1
R01$1,911,016 · 2
U01$1,569,701 · 1
R41$900,885 · 2
R21$743,819 · 2
P30$0 · 1
Top collaborators
- Thaddeus J Wadas2 shared
Others in their field
Top investigators on “Cancer Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$394,493,843
- Gregory H Reaman · National Childhood Cancer Foundation$172,801,935
- Richard A Gibbs · Baylor College Of Medicine$159,160,442
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Mary M Horowitz · Medical College Of Wisconsin$153,900,671
- William George Nelson · Johns Hopkins University$111,434,918
Research focus
Cancer CellFluorouracilPharmaceutical PreparationsMetabolismPropertyFluoropyrimidineTumorColon CarcinomaColorectal CancerRegimenThymidylate SynthaseCytotoxicityBiodistributionPolymersToxic EffectMetastatic ColorectalCollaborationsCancer ModelGenerationsColon Cancer PatientsPre-ClinicalClinical DevelopmentLaboratoriesDrug Kinetics
Grant awards (21)
Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer$579,073
R01 · FY2025 · CA · contact PI
Modified Thrombin Binding Aptamer Treatment of CRC Metastasis$399,968
R41 · FY2025 · CA · contact PI
Improved Treatment of Colorectal Cancer with CF10$1,018,545
R42 · FY2024 · CA · contact PI
Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer$549,986
R01 · FY2024 · CA · contact PI
Improved Treatment of Colorectal Cancer with CF10$964,465
R42 · FY2023 · CA · contact PI
Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer$592,748
R01 · FY2023 · CA · contact PI
Improved Treatment of Colorectal Cancer with CF10 Diversity Supplement$104,488
R41 · FY2022 · CA · contact PI
Improved Treatment of Colorectal Cancer with CF10$396,429
R41 · FY2021 · CA · contact PI
Aptamer-Based Radiopharmaceuticals for the Targeted Alpha Particle Therapy of Prostate Cancer$212,522
R21 · FY2020 · CA
Aptamer-based radiopharmaceuticals for the targeted alpha particle therapy of prostate cancer$165,517
R21 · FY2019 · CA
Development of a CF10 Predictive Gene Signature in CRC Organoids.$163,505
R21 · FY2019 · CA · contact PI
Development of a CF10 Predictive Gene Signature in CRC Organoids.$202,275
R21 · FY2018 · CA · contact PI
DNA-DIRECTED EFFECTS OF FdUMP(N)$300,196
U01 · FY2009 · CA · contact PI
DNA-DIRECTED EFFECTS OF FdUMP(N)$300,200
U01 · FY2008 · CA · contact PI
DNA-DIRECTED EFFECTS OF FdUMP(N)$306,143
U01 · FY2007 · CA · contact PI
DNA-DIRECTED EFFECTS OF FdUMP(N)$315,288
U01 · FY2006 · CA · contact PI
DNA-DIRECTED EFFECTS OF FdUMP(N)$347,874
U01 · FY2005 · CA
CORE--NMR$0
P30 · FY2002 · CA
CORE--NMR$0
P30 · FY2001 · CA
IMPACT OF 5FU ON THE STRUCTURE OF THE U4/U6 COMPLEX$189,209
R01 · FY2000 · CA
CORE--NMR$0
P30 · FY2000 · CA